Sandbox sepsis rsg2

Empiric Antibiotic Therapy

Unclear infection source

Doripenem 500 mg IV q8h OR Ertapenem 1 gm IV q24h OR Imipenem 0.5 gm IV q6h OR Meropenem 1 gm IV q8h AND Vancomycin 1 gm IV q12h

Low prevalence of ESBL and/or carbapenemase producing aerobic gram-negative bacilli

Piperacillin-Tazobactam 3.375 gm IV q4h AND Vancomycin 1 gm IV q12h

High prevalence of ESBL and/or carbapenemase producing aerobic gram-negative bacilli

Colistin 2.5 mg/kg then 1.5 mg/kg IV q12h AND Meropenem 1 gm IV q8h AND Vancomycin 1 gm IV q12h

Biliary source

Ampicillin-Sulbactam 3 gm IV q6h OR Piperacillin-Tazobactam 3.375 gm IV q4h OR Ticarcillin-Clavulanate 3.1 gm IV q4h

Community-acquired pneumonia

Levofloxacin 750 mg IV q24h OR Moxifloxacin 400 mg IV q24h AND Piperacillin-Tazobactam 3.375 gm IV q4h AND Vancomycin 1 gm IV q12h

History of intravenous drug use with high prevalence of MRSA

Vancomycin 1 gm IV q12h

Sepsis associated with petechiae

Ceftriaxone 2 gm IV q12h